REGENXBIO settles GSK royalty dispute for $10M, resolves sublicense fee claims

Filed March 20, 2026 · Period ending March 18, 2026 · ~1 min read

Key Changes

• high

  Company will pay GSK $10 million within three business days to settle dispute over allegedly underpaid sublicense fees and royalties from REGENXBIO's sublicensees under a 2009 license agreement.

  Item 1.01 verify on EDGAR →
• medium

  Settlement includes mutual releases of all past claims and certain future claims related to the GSK sublicense agreement, providing legal closure on historical disputes and limiting future litigation risk.

  Item 1.01 verify on EDGAR →
• medium

  REGENXBIO will continue using its existing methodology to calculate and pay GSK sublicense fees going forward, suggesting parties agreed to disagree on past amounts but maintain current payment structure.

  Item 1.01 verify on EDGAR →